drugset
drugset / Trial / NCT07435038

Study of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

NCT07435038 ↗

Phase 1/2 Not yet recruiting 120 enrolled Betta Pharmaceuticals Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

Evaluate the safety and tolerability of BPI-572270 in adult patients with specific RAS mutant advanced solid tumors.

Timeline

Start
2026-02-12
Primary completion
2028-12-28
Completion
2029-10-28

Drugs

EvaluationDrugModalityDoseRoute
Subject BPI-572270 Unknown — Oral

Indications

colorectal cancer non-small cell lung carcinoma pancreatic ductal adenocarcinoma